[Ximelagatran: a promising new drug for oral anticoagulation].
Ximelagatran is the first orally available direct thrombin inhibitor. Ximelagatran is a pro-drug with an antithrombotic effect comparable to that of warfarin. Clinical studies have demonstrated that ximelagatran is as effective as warfarin in the prevention of deep-vein thrombosis, of stroke in patients with nonvalvular atrial fibrillation, and of the adverse cardiovascular events in patients with recent myocardial infarction. Ximelagatran can be administered without any need of laboratory test.
Scardi
Sabino
S
Centro Cardiovascolare Azienda Sanitaria Triestina, Via Farneto, 3, 34100 Trieste. sabino.scardi@assl.sanita.fvg.it
Giansante
Carlo
C
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001384:Azetidines / Q000008:administration & dosage / Q000627:therapeutic use*; D001596:Benzylamines; D002986:Clinical Trials as Topic; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; C426686:ximelagatran